STAT+: Federal regulators invite industry, researchers, and lobbyists to closed-door meetings on clinical AI

STAT PlusExclusive Federal regulators invite industry, researchers, and lobbyists to closed-door meetings on clinical AI The meetings with FDA, CMS, and HHS officials have not been publicly announced Manage alerts for this article Email this article Share this article By Mario AguilarAug. 5, 2026 Health Tech Correspondent Mario Aguilar[email protected]Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer wearables. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter.

You can reach Mario on Signal at mariojoze.13. Federal health officials held closed-door conversations with prominent technology companies last month as the health department and its subagencies aim to safely boost adoption of clinical artificial intelligence. During a “clinical AI demo day” on July 8 at the Food and Drug Administration’s White Oak headquarters, officials from the FDA and the Centers for Medicare and Medicaid Services hosted leaders from 10 companies, according to an agenda for the event reviewed by STAT: Anthropic, Counsel Health, Curai, K Health, Microsoft AI, Amazon One Medical, Doctronic, Ellipsis Health, Hippocratic AI, and Welldoc.Advertisement STAT spoke with four companies that attended, Counsel Health, K Health, Hippocratic AI, and Ellipsis Health, whose leaders summarized their comments to regulators.

The meeting was meant to offer federal health officials firsthand experience with AI doctor technology as it exists today. For the assembled companies, including powerful technology giants and startups funded by influential investors such as Andreessen Horowitz and Khosla Ventures, the event offered a significant opportunity to help shape policy as officials wrestle with regulating health AI and how to pay for it. STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In Artificial intelligence, Policy, STAT+ Submit a correction requestReprints Mario Aguilar Health Tech Correspondent Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer wearables.

He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can reach Mario on Signal at mariojoze.13. Newsletter Tech is transforming health care and life sciences.

Our original reporting is here to keep you ahead of the curve. Recommended Exclusive August 5, 2026 STAT Plus: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safety Exclusive August 5, 2026 STAT Plus: Senate inquiry suggests Trump administration softened kratom and tobacco policies in quid pro quo Advertisement Exclusive August 4, 2026 STAT Plus: Startup promising to scale custom CRISPR therapies abruptly scraps plans Exclusive August 3, 2026 STAT Plus: Eli Lilly to allow more patients to apply for special access to unapproved obesity drug Exclusive July 23, 2026 Filing of bipartisan Senate bill boosts momentum for office of men’s health Subscriber Picks